Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera rises on strong Q3 sales of COVID drug

** Shares of biotechnology company AbCellera Biologics Inc
 ABCL.O  up 9.9% premarket at $13.45
    ** Co late on Tuesday reported quarterly sales above market
estimates, mainly due to strong demand for COVID-19 antibody
drug bebtelovimab
    ** Bebtelovimab is the second COVID-19 antibody discovered
by ABCL and was licensed to Eli Lilly and Co  LLY.N  for
development, manufacturing and commercialization
    ** Q3 revenue of $101.38 mln beats estimates of $74.95 mln -
Refinitv IBES data
    ** Brokerage SVB Securities raises PT to $20 from $13 and
views co as "a promising antibody discovery platform" with
strong cash position to fund more programs to grow its pipeline
    ** Co has a cash position of $868 mln 
    ** Up to Tuesday's close, stock had fallen ~15% YTD vs a
~12% decline in the Nasdaq Biotechnology index  .NBI 
 (Reporting by Sriparna Roy)
 ((Sriparna.roy@thomsonreuters.com))

Recent news on AbCellera Biologics

See all news